Melatonin regulates Sirt1/Nrf2/GPX4 pathway to inhibit ferroptosis and alleviate myocardial injury caused by sepsis

Figure 6 Sirtuin 1 inhibition weakens melatonin-induced sirtuin 1/nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling and cytoprotection in HL-1 cells. A and B: Representative immunoblots and quantification of sirtuin 1, nuclear factor erythroid 2-related factor 2, and heme oxygenase-1 in HL-1 cells treated with lipopolysaccharide, melatonin, or melatonin plus the sirtuin 1 inhibitor EX527 (glyceraldehyde-3-phosphate dehydrogenase as control); C: Cell viability assessed by cell counting kit-8 under the same conditions. Data are presented as mean ± SD from three independent biological experiments (each measured in technical triplicate). One-way analysis of variance with Bonferroni post-hoc testing. ^aP < 0.01 vs control; ^bP < 0.01 vs lipopolysaccharide; ^cP < 0.01 vs lipopolysaccharide plus melatonin. Ctrl: Control; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; HO-1: Heme oxygenase-1; LPS: Lipopolysaccharide; LPS + Mel: Lipopolysaccharide plus melatonin; LPS + Fer-1: Lipopolysaccharide plus ferrostatin-1; Nrf2: Nuclear factor erythroid 2-related factor 2; Sirt1: Sirtuin 1.